Literature DB >> 28024090

Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.

Kenneth J Smith1, Richard K Zimmerman2, Mary Patricia Nowalk2, Chyongchiou J Lin2.   

Abstract

OBJECTIVES: To estimate the cost-effectiveness of an intervention to increase pneumococcal, influenza, and pertussis-containing vaccine uptake in adults aged 65 and older in primary care practices.
DESIGN: Markov decision analysis model, comparing the cost-effectiveness of the 4 Pillars Practice Transformation Program with no intervention.
SETTING: Diverse primary care practices in two U.S. cities. PARTICIPANTS: Clinical trial participants aged 65 and older. MEASUREMENTS: Quality-adjusted life years (QALYs), public health outcomes, and costs. Vaccination rates and intervention costs were derived from a randomized controlled cluster trial. Other parameters were derived from the medical literature and Centers for Disease Control and Prevention data. All parameters were individually and simultaneously varied over their distributions.
RESULTS: With the intervention program and extrapolating over 10 years, there would be approximately 60,920 fewer influenza cases, 2,031 fewer pertussis cases, and 13,842 fewer pneumococcal illnesses in adults aged 65 and older. Total per-person vaccination and illness costs with the intervention were $23.93 higher than without the intervention, with a concurrent increase in effectiveness of 0.0031 QALYs, or $7,635 per QALY gained. In sensitivity analyses, no individual parameter variation caused the intervention to cost more than $50,000 per QALY gained.
CONCLUSIONS: Implementing an intervention based on the 4 Pillars Practice Transformation Program is a cost-effective undertaking in primary care practices for individuals aged 65 and older, with predicted public health benefits.
© 2016, Copyright the Authors Journal compilation © 2016, The American Geriatrics Society.

Entities:  

Keywords:  Tdap vaccine; adult vaccination; cost-effectiveness; influenza vaccine; pneumococcal vaccine

Mesh:

Substances:

Year:  2016        PMID: 28024090      PMCID: PMC5397321          DOI: 10.1111/jgs.14588

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  25 in total

1.  Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years.

Authors:  Derek Weycker; Reiko Sato; David Strutton; John Edelsberg; Mark Atwood; Lisa A Jackson
Journal:  Vaccine       Date:  2012-06-20       Impact factor: 3.641

2.  Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups.

Authors:  Constantinos I Michaelidis; Richard K Zimmerman; Mary Patricia Nowalk; Kenneth J Smith
Journal:  Vaccine       Date:  2011-03-12       Impact factor: 3.641

3.  Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.

Authors:  Charles Stoecker; Lindsay Kim; Ryan Gierke; Tamara Pilishvili
Journal:  J Gen Intern Med       Date:  2016-03-14       Impact factor: 5.128

Review 4.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

Authors:  Michael T Osterholm; Nicholas S Kelley; Alfred Sommer; Edward A Belongia
Journal:  Lancet Infect Dis       Date:  2011-10-25       Impact factor: 25.071

5.  Cluster randomized trial of a toolkit and early vaccine delivery to improve childhood influenza vaccination rates in primary care.

Authors:  Richard K Zimmerman; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Kristin Hannibal; Krissy K Moehling; Hsin-Hui Huang; Annamore Matambanadzo; Judith Troy; Norma J Allred; Greg Gallik; Evelyn C Reis
Journal:  Vaccine       Date:  2014-04-29       Impact factor: 3.641

6.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Authors:  Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney
Journal:  Lancet Infect Dis       Date:  2015-02-03       Impact factor: 25.071

7.  Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Authors:  Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

8.  The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial.

Authors:  T M Govaert; C T Thijs; N Masurel; M J Sprenger; G J Dinant; J A Knottnerus
Journal:  JAMA       Date:  1994-12-07       Impact factor: 56.272

9.  Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis.

Authors:  Constantinos I Michaelidis; Richard K Zimmerman; Mary Patricia Nowalk; Kenneth J Smith
Journal:  Value Health       Date:  2013 Mar-Apr       Impact factor: 5.725

10.  Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season.

Authors:  Carrie Reed; Inkyu Kevin Kim; James A Singleton; Sandra S Chaves; Brendan Flannery; Lyn Finelli; Alicia Fry; Erin Burns; Paul Gargiullo; Daniel Jernigan; Nancy Cox; Joseph Bresee
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-12-12       Impact factor: 17.586

View more
  5 in total

1.  Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.

Authors:  Kenneth J Smith; Mary Patricia Nowalk; Chyongchiou J Lin; Richard K Zimmerman
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

2.  Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  J Am Geriatr Soc       Date:  2020-02-22       Impact factor: 5.562

3.  Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Hawre Jalal; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  Vaccine       Date:  2021-05-25       Impact factor: 4.169

4.  Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Richard K Zimmerman; Kenneth J Smith; Chyongchiou J Lin
Journal:  BMC Infect Dis       Date:  2018-01-25       Impact factor: 3.090

Review 5.  Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries.

Authors:  Molly Sauer; Prarthana Vasudevan; Ankita Meghani; Karuna Luthra; Cristina Garcia; Maria Deloria Knoll; Lois Privor-Dumm
Journal:  Vaccine       Date:  2021-02-19       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.